Table 3.
Estimates of the association between vaccination and SARS-CoV-2 infection and effectiveness of inactivated SARS-CoV-2 vaccines.
| Vaccinated | Unvaccinated | 1 dose ORadj (95%CI) | 1 dose VEadj (%, 95%CI) | Vaccinated | Unvaccinated | 2 doses ORadj (95%CI) | 2 doses VEadj (%, 95%CI) | |
|---|---|---|---|---|---|---|---|---|
| The whole population | ||||||||
| Control | 66 | 147 | Reference | – | 79 | 147 | Reference | – |
| Overall cases | 20 | 44 | 0.86 (0.45–1.60) | 13.8 (−60.2, 54.8) | 10 | 44 | 0.41 (0.19–0.84) | 59.0 (16.0, 81.6) |
| Mild cases | 2 | 6 | 1.13 (0.16–5.53) | −13.4 (−452.5, 84.3) | 4 | 6 | 1.29 (0.32–4.69) | −29.4 (−369.4, 67.9) |
| Moderate cases | 18 | 36 | 0.89 (0.45–1.73) | 11.2 (−72.5, 55.5) | 6 | 36 | 0.30 (0.11–0.70) | 70.2 (29.6, 89.3) |
| Severe cases | 0 | 2 | – | – | 0 | 2 | – | 100 |
| 18–39 years | ||||||||
| Control | 28 | 86 | Reference | – | 39 | 86 | Reference | – |
| Overall cases | 4 | 18 | 0.63 (0.17–1.90) | 36.9 (−89.9, 83.1) | 5 | 18 | 0.63 (0.20–1.74) | 37.0 (−73.9, 80.5) |
| Mild cases | 2 | 5 | 1.54 (0.21–8.14) | −53.7 (−714.3, 79.5) | 2 | 5 | 0.91 (0.13–4.47) | 9.3 (−346.9, 87.5) |
| Moderate cases | 2 | 13 | 0.38 (0.06–1.54) | 62.2 (−54.1, 94.5) | 3 | 13 | 0.54 (0.12–1.85) | 46.1 (−85.2, 88.4) |
| Severe cases | 0 | 0 | – | – | 0 | 0 | – | – |
| 40–59 years | ||||||||
| Control | 38 | 61 | Reference | – | 40 | 61 | Reference | – |
| Overall cases | 16 | 26 | 0.98 (0.44–2.15) | 1.8 (−115.3, 56.0) | 5 | 26 | 0.26 (0.08–0.76) | 72.5 (23.9–91.6) |
| Mild cases | 0 | 1 | – | – | 2 | 1 | 2.62 (0.23–59.03) | −161.9 (−5803.3, 76.8) |
| Moderate cases | 16 | 23 | 1.11 (0.49–2.47) | −11.0 (−147.3, 50.8) | 3 | 23 | 0.19 (0.04–0.63) | 80.6 (37.1, 95.7) |
| Severe cases | 0 | 2 | – | – | 0 | 2 | – | 100 |
| Malesa | ||||||||
| Control | 40 | 91 | Reference | – | 46 | 91 | Reference | – |
| Overall cases | 7 | 17 | 0.89 (0.32–2.27) | 11.2 (−126.7, 68.2) | 5 | 17 | 0.58 (0.18–1.58) | 41.9 (−57.5, 81.8) |
| Mild cases | 1 | 4 | 0.72 (0.04–5.39) | 27.8 (−438.9, 96.4) | 2 | 4 | 1.00 (0.13–5.37) | −0.1 (−437.4, 86.6) |
| Moderate cases | 6 | 13 | 0.93 (0.30–2.58) | 7.2 (−157.6, 69.8) | 3 | 13 | 0.45 (0.10–1.49) | 54.8 (−49.2, 90.0) |
| Severe cases | 0 | 0 | – | – | 0 | 0 | – | – |
| Femalesa | ||||||||
| Control | 26 | 56 | Reference | – | 33 | 56 | Reference | – |
| Overall cases | 13 | 27 | 0.85 (0.36–1.98) | 14.6 (−97.8, 64.3) | 5 | 27 | 0.30 (0.09–0.82) | 70.4 (18.4, 91.0) |
| Mild cases | 1 | 2 | 1.08 (0.05–11.74) | −8.0 (−1074.0, 95.0) | 2 | 2 | 1.78 (0.20–15.76) | −78.4 (−1476.2, 79.7) |
| Moderate cases | 12 | 23 | 0.87 (0.35–2.11) | 13.2 (−111.2, 65.5) | 3 | 23 | 0.21 (0.05–0.69) | 79.1 (30.9, 95.4) |
| Severe cases | 0 | 2 | – | – | 0 | 2 | – | 100 |
Note: OR were adjusted for age and gender. The “–” indicated no data.
a
OR only adjusted for age.